Suven Secures Two Product Patents from Mexico, New Zealand | CORPORATE ETHOS

Suven Secures Two Product Patents from Mexico, New Zealand

By: | August 7, 2018
suven life sciences

Aug 7: Hyderabad-based biopharma major Suven Life Sciences Ltd on Tuesday announced that the company has been granted one product patent from Mexico (354852) and another one product patent from New Zealand (734400) corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2030 and 2036 respectively.

According to the company, the granted claims of the patents include the class of selective H3 and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.

Suven shares were trading at Rs 226.35, up 0.69% from the previous closing of Rs 225.10, on BSE at 11.24 am today.